As MYCN gene amplification is the strongest genetic predictor for poor prognosis in neuroblastoma and has been shown to drive polyamine synthesis and uptake with ODC1 and SLC3A2 being identified as bona fide MYCN targets [10, 29, 30], we assessed whether the observed association between high ATP13A3 expression and poor outcome may be mediated by MYCN amplification. Here, SLC3A2 is linked to neuroblastoma.